1
|
de Oliveira ÉA, Faintuch BL, Seo D, Barbezan AB, Funari A, Targino RC, Moro AM. Radiolabeled GX1 Peptide for Tumor Angiogenesis Imaging. Appl Biochem Biotechnol 2018; 185:863-874. [DOI: 10.1007/s12010-018-2700-z] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2017] [Accepted: 01/15/2018] [Indexed: 02/06/2023]
|
2
|
Biber Muftuler FZ, Unak P. A perspective on 99mTc and 125/131I labeled receptor targeted compounds and their in vitro/in vivo affinities. J Radioanal Nucl Chem 2017. [DOI: 10.1007/s10967-017-5353-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
3
|
De K, Banerjee I, Sinha S, Ganguly S. Synthesis and exploration of novel radiolabeled bombesin peptides for targeting receptor positive tumor. Peptides 2017; 89:17-34. [PMID: 28088445 DOI: 10.1016/j.peptides.2017.01.002] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/09/2016] [Revised: 12/16/2016] [Accepted: 01/04/2017] [Indexed: 11/19/2022]
Abstract
Increasing evidence of peptide receptor overexpression in various cancer cells, warrant the development of receptor specific radiolabeled peptides for molecular imaging and therapy in nuclear medicine. Gastrin-releasing-peptide (GRP) receptor, are overexpressed in a variety of human cancer cells. The present study report the synthesis and biological evaluation of new bombesin (BBN) analogs, HYNIC-Asp-[Phe13]BBN(7-13)-NH-CH2-CH2-CH3:BA1, HYNIC-Pro-[Tyr13Met14]BBN(7-14)NH2:BA2 as prospective tumor imaging agent with compare to BBN(7-14)NH2:BS as standard. The pharmacophores were radiolabeled in high yields with 99mTc, characterized for their stability in serum and saline, cysteine/histidine and were found to be substantially stable. Internalization/externalization and receptor binding studies were assessed using MDA-MB-231 cells and showed high receptor binding-affinity and favourable internalization. Fluorescence studies revealed that BA1 changed the morphology of the cells and could localize in the nucleus more effectively than BA2/BS. Cell-viability studies displayed substantial antagonistic and nuclear-internalization effect of BA1. BA1 also exhibited antiproliferative effect on MDA-MB-231 cell by inducing apoptosis. In vivo behaviour of the radiopeptides was evaluated in GRP receptor positive tumor bearing mice. The 99mTc-BA1/99mTc-BA2 demonstrated rapid blood/urinary clearance through the renal pathway and comparatively more significant tumor uptake image and favourable tumor-to-non-target ratios provided by 99mTc-BA1. The specificity of the in vivo uptake was confirmed by co-injection with BS. Moreover, 99mTc-BA1 provided a much clearer tumor image in scintigraphic studies than others. Thus the combination of favourable in vitro and in vivo properties renders BA1 as more potential antagonist bombesin-peptide for targeting GRP-receptor positive tumor. These properties are encouraging to carry out further experiments for non-invasive receptor targeting potential diagnostinc and therapeutic agent for tumors.
Collapse
Affiliation(s)
- Kakali De
- Infectious Diseases and Immunology Division (Nuclear Medicine Laboratory), CSIR-Indian Institute of Chemical Biology, 4 Raja S C Mullick Road, Kolkata, 700032, West Bengal, India.
| | - Indranil Banerjee
- Infectious Diseases and Immunology Division (Nuclear Medicine Laboratory), CSIR-Indian Institute of Chemical Biology, 4 Raja S C Mullick Road, Kolkata, 700032, West Bengal, India
| | - Samarendu Sinha
- Regional Radiation Medicine Center, Thakurpukur Cancer Center and Welfare Home Campus, Kolkata, 700 063, India
| | - Shantanu Ganguly
- Regional Radiation Medicine Center, Thakurpukur Cancer Center and Welfare Home Campus, Kolkata, 700 063, India
| |
Collapse
|
4
|
de Oliveira ÉA, Faintuch BL, Targino RC, Moro AM, Martinez RCR, Pagano RL, Fonoff ET, Carneiro CDG, Garcez AT, Faria DDP, Buchpiguel CA. Evaluation of GX1 and RGD-GX1 peptides as new radiotracers for angiogenesis evaluation in experimental glioma models. Amino Acids 2015; 48:821-831. [PMID: 26592499 DOI: 10.1007/s00726-015-2130-y] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2015] [Accepted: 11/04/2015] [Indexed: 01/31/2023]
Abstract
Gliomas are the most common type among all central nervous system tumors. The aggressiveness of gliomas is correlated with the level of angiogenesis and is often associated with prognosis. The aim of this study is to evaluate the novel GX1 peptide and the heterodimer RGD-GX1 radiolabeled with technetium-99m, for angiogenesis detection in glioma models. Radiolabeling and radiochemical controls were assessed for both radioconjugates. In vitro binding studies in glioma tumor cells were performed, as well as biodistribution in SCID mice bearing tumor cells, in order to evaluate the biological behavior and tumor uptake of the radiocomplexes. Blocking and imaging studies were also conducted. MicroSPECT/CT images were acquired in animals with experimentally implanted intracranial tumor. Open field activity was performed to evaluate behavior, as well as perfusion and histology analysis. The radiochemical purity of both radiotracers was greater than 96 %. In vitro binding studies revealed rather similar binding profi le for each molecule. The highest binding was for RGD-GX1 peptide at 120 min in U87MG cells (1.14 ± 0.35 %). Tumor uptake was also favorable for RGD-GX1 peptide in U87MG cells, reaching 2.96 ± 0.70 % at 1 h p.i. with 47 % of blocking. Imaging studies also indicated better visualization for RGD-GX1 peptide in U87MG cells. Behavior evaluation pointed brain damage and histology studies confirmed actual tumor in the uptake site. The results with the angiogenesis seeking molecule (99m)Tc-HYNIC-E-[c(RGDfk)-c(GX1)] were successful, and better than with (99m)Tc-HYNIC-PEG4-c(GX1). Future studies targeting angiogenesis in other glioma and nonglioma tumor models are recommended.
Collapse
Affiliation(s)
- Érica Aparecida de Oliveira
- Radiopharmacy Center, Institute of Energy and Nuclear Research, Av. Prof. Lineu Prestes, 2242, São Paulo, 05508-000, Brazil. .,School of Pharmaceutical Sciences, University of Sao Paulo, Av. Prof. Lineu Prestes, 580 Bloco 17, São Paulo, 05508-900, Brazil.
| | - Bluma Linkowski Faintuch
- Radiopharmacy Center, Institute of Energy and Nuclear Research, Av. Prof. Lineu Prestes, 2242, São Paulo, 05508-000, Brazil
| | - Roselaine Campos Targino
- Laboratory of Biopharmacology in Animal Cells, Butantan Institute, Av. Vital Brasil, 1500, Sao Paulo, 05503-900, Brazil
| | - Ana Maria Moro
- Laboratory of Biopharmacology in Animal Cells, Butantan Institute, Av. Vital Brasil, 1500, Sao Paulo, 05503-900, Brazil
| | - Raquel Chacon Ruiz Martinez
- Laboratory of Neuromodulation and Experimental Pain, Teaching and Research Institute, Hospital Sírio-Libanês, Rua Professor Daher Cutait, 69, Sao Paulo, 01308-060, Brazil
| | - Rosana Lima Pagano
- Laboratory of Neuromodulation and Experimental Pain, Teaching and Research Institute, Hospital Sírio-Libanês, Rua Professor Daher Cutait, 69, Sao Paulo, 01308-060, Brazil
| | - Erich Talamoni Fonoff
- Laboratory of Neuromodulation and Experimental Pain, Teaching and Research Institute, Hospital Sírio-Libanês, Rua Professor Daher Cutait, 69, Sao Paulo, 01308-060, Brazil.,Division of Functional Neurosurgery, Institute of Psychiatry of Hospital das Clinicas and Department of Neurology, School of Medicine, University of São Paulo, R. Dr. Ovídio Pires de Campos, 785, São Paulo, 01060-970, Brazil
| | - Camila de Godoi Carneiro
- Nuclear Medicine Laboratory (LIM 43), Medical School, University of São Paulo, Av. Dr. Enéas de Carvalho Aguiar, s/nº-Rua 1, Sao Paulo, 05403-900, Brazil
| | - Alexandre Teles Garcez
- Nuclear Medicine Laboratory (LIM 43), Medical School, University of São Paulo, Av. Dr. Enéas de Carvalho Aguiar, s/nº-Rua 1, Sao Paulo, 05403-900, Brazil
| | - Daniele de Paula Faria
- Nuclear Medicine Laboratory (LIM 43), Medical School, University of São Paulo, Av. Dr. Enéas de Carvalho Aguiar, s/nº-Rua 1, Sao Paulo, 05403-900, Brazil
| | - Carlos Alberto Buchpiguel
- Nuclear Medicine Laboratory (LIM 43), Medical School, University of São Paulo, Av. Dr. Enéas de Carvalho Aguiar, s/nº-Rua 1, Sao Paulo, 05403-900, Brazil
| |
Collapse
|
5
|
Oliveira EA, Faintuch BL. Radiolabeling and biological evaluation of the GX1 and RGD-GX1 peptide sequence for angiogenesis targeting. Nucl Med Biol 2014; 42:123-30. [PMID: 25311749 DOI: 10.1016/j.nucmedbio.2014.09.004] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2014] [Revised: 09/03/2014] [Accepted: 09/15/2014] [Indexed: 11/30/2022]
Abstract
INTRODUCTION Aiming to develop a novel (99m)Tc-labeled imaging agent, for angiogenesis and tumor receptors, two peptides obtained from phage display library, namely GX1 and the heterodimer RGD-GX1, were synthesized in a cyclic conformation. They were radiolabeled with (99m)Tc, employing the HYNIC chelator, for radiochemical evaluation and biological properties. METHODS Radiolabeling, radiochemical control, plasma protein binding, and partition coefficient were assessed for both radioconjugates. Biodistribution in healthy Balb/c mice was carried out, in order to evaluate the biological behaviour of the radiocomplexes. RESULTS The conjugates displayed a rather similar pharmacokinetic profile. They were prepared with high radiochemical purity (>96%), and both were hydrophilic (log P of -2.25 and -2.51 respectively). Preferential renal excretion was observed. Kidney uptake (42.31±5.35 %ID/g) for (99m)Tc-HYNIC-E-[c(RGDfk)-c(GX1)], 1h post-injection was about three times higher than the uptake of (99m)Tc-HYNIC-PEG4-c(GX1) (11.92±4.77%ID/g). Total blood, bone and muscle values revealed a slightly slower clearance for the RGD-GX1 radiocomplex. CONCLUSION The high radiochemical purity achieved, and the similar in vivo profile observed for both radioconjugates, make them potential candidates for radiopharmaceuticals for tumor imaging. Further investigations of binding affinity, and uptake of GX1 and RGD-GX1 peptides in tumor models, are warranted.
Collapse
Affiliation(s)
- E A Oliveira
- Radiopharmacy, Institute of Energy and Nuclear Research, Sao Paulo, SP, Brazil, Av. Prof. Lineu Prestes, 2242 05508-000 São Paulo, SP, Brazil.
| | - B L Faintuch
- Radiopharmacy, Institute of Energy and Nuclear Research, Sao Paulo, SP, Brazil, Av. Prof. Lineu Prestes, 2242 05508-000 São Paulo, SP, Brazil
| |
Collapse
|
6
|
Altıparmak B, Lambrecht FY, Er O. Design of (99m) Tc-DTPA-CLP and preliminary evaluation in rats. Chem Biol Drug Des 2014; 83:362-6. [PMID: 24148110 DOI: 10.1111/cbdd.12253] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2013] [Revised: 09/12/2013] [Accepted: 10/15/2013] [Indexed: 11/28/2022]
Abstract
Radiopharmaceuticals are localized in (malignant) tumor tissues by different mechanisms. One of these mechanisms, gelatinase enzyme activity, is associated with poor prognosis in cancer patients and potential targets for tumor imaging. There are some gelatinases to be associated with metastatic potential for tumor imaging to possibly predict metastases. In this study, a cyclic decapeptide conjugate, DTPA-CLP (DTPA-Cys-Leu-Pro-Gly-His-Trp-Gly-Phe-Pro-Ser-Cys), was selected as a peptide conjugate because of its selective inhibitory activity toward gelatinases. Peptide-conjugated DTPA-CLP was labeled with (99m) Tc with a radiolabeling efficiency of 97.0 ± 2.8%. After determining optimization conditions for radiolabeling, a biodistribution study of radiolabeled peptide in albino Wistar rats was performed. According to biodistribution data, (99m) Tc-DTPA-CLP showed high uptake in the lung, liver, uterus, and spleen. These results show that (99m) Tc-DTPA-CLP may be used for the imaging of gelatinase activity in metastatic tumors.
Collapse
Affiliation(s)
- Burcu Altıparmak
- Department of Nuclear Applications, Institute of Nuclear Science, Ege University, Bornova, Izmir, 35100, Turkey
| | | | | |
Collapse
|
7
|
Erfani M, Zarrabi Ahrabi N, Shafiei M, Shirmardi SP. A (99m) Tc-tricine-HYNIC-labeled peptide targeting the neurotensin receptor for single-photon imaging in malignant tumors. J Labelled Comp Radiopharm 2014; 57:125-31. [PMID: 24395489 DOI: 10.1002/jlcr.3176] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/17/2013] [Revised: 11/19/2013] [Accepted: 11/27/2013] [Indexed: 11/06/2022]
Abstract
In this study, a new neurotensin (NT) analog was labeled with (99m) Tc via HYNIC chelator and tricine as coligand and investigated further. An NT (7-13) analog was prepared, and labeling with (99m) Tc was performed. The internalization rate and biodistribution of radiopeptide were studied in HT-29 cells and nude mice bearing tumor, respectively. Radiolabeling with (99m) Tc was performed at high specific activities (54 MBq/nmol) with an acceptable labeling yield (>95%). In vitro cell line studies showed a specific internalization uptake up to 13.23 ± 0.45% during 4 h which was blocked in the presence of excess cold peptide to 0.83 ± 0.15%. In biodistribution studies, uptake was observed in NT receptor-positive organs so that after 1 h the uptakes in mouse intestine and tumor were 1.23 ± 0.16% ID/g and 1.12 ± 0.11% ID/g, respectively. In animals co-injected with excess cold peptide, reduction uptake in tumor and intestines were 73% (1.10% vs. 0.29% ID/g at 4 h) and 61% (1.22% vs. 0.47% ID/g at 4 h) respectively. Predominant renal excretion pathway with a highest accumulation of activity in bladder was observed for this radiopeptide. This radiolabeled peptide could be a candidate for detection of NT positive tumors.
Collapse
Affiliation(s)
- Mostafa Erfani
- Radiation Application Research School, Nuclear Science and Technology Research Institute (NSTRI), Atomic Energy Organization of Iran (AEOI), PO Box: 11365-3486, end of Karegar Ave., Tehran, Iran
| | | | | | | |
Collapse
|
8
|
Yurt Lambrecht F, Durkan K, Özgür A, Gündüz C, Avcı ÇB, Susluer SY. In vitroevaluation of99mTc-EDDA/tricine-HYNIC-Q-Litorin in gastrin-releasing peptide receptor positive tumor cell lines. J Drug Target 2013; 21:383-8. [DOI: 10.3109/1061186x.2012.757772] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
|
9
|
Varshney R, Hazari PP, Fernandez P, Schulz J, Allard M, Mishra AK. (68)Ga-labeled bombesin analogs for receptor-mediated imaging. Recent Results Cancer Res 2013; 194:221-256. [PMID: 22918762 DOI: 10.1007/978-3-642-27994-2_12] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Abstract
Targeted receptor-mediated imaging techniques have become crucial tools in present targeted diagnosis and radiotherapy as they provide accurate and specific diagnosis of disease information. Peptide-based pharmaceuticals are gaining popularity, and there has been vast interest in developing (68)Ga-labeled bombesin (Bn) analogs. The gastrin-releasing peptide (GRP) family and its Bn analog have been implicated in the biology of several human cancers. The three bombesin receptors GRP, NMB, and BRS-3 receptor are most frequently ectopically expressed by common, important malignancies. The low expression of Bn/GRP receptors in normal tissue and relatively high expression in a variety of human tumors can be of biological importance and form a molecular basis for Bn/GRP receptor-mediated imaging. To develop a Bn-like peptide with favorable tumor targeting and pharmacokinetic characteristics for possible clinical use, several modifications in the Bn-like peptides, such as the use of a variety of chelating agents, i.e., acyclic and macrocyclic agents with different spacer groups and with different metal ions (gallium), have been performed in recent years without significant disturbance of the vital binding scaffold. The favorable physical properties of (68)Ga, i.e., short half-life, and the fast localization of small peptides make this an ideal combination to study receptor-mediated imaging in patients.
Collapse
|
10
|
De K, Chandra S, Ganguly S, Sarkar B, Misra M. Synthesis and radiobiological evaluation of a new 99mTc-labeled small peptide: 99mTc-YGGSLAK as imaging agent. J Labelled Comp Radiopharm 2011. [DOI: 10.1002/jlcr.1883] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
11
|
Bombesin functionalized gold nanoparticles show in vitro and in vivo cancer receptor specificity. Proc Natl Acad Sci U S A 2010; 107:8760-5. [PMID: 20410458 DOI: 10.1073/pnas.1002143107] [Citation(s) in RCA: 228] [Impact Index Per Article: 16.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022] Open
Abstract
Development of cancer receptor-specific gold nanoparticles will allow efficient targeting/optimum retention of engineered gold nanoparticles within tumors and thus provide synergistic advantages in oncology as it relates to molecular imaging and therapy. Bombesin (BBN) peptides have demonstrated high affinity toward gastrin-releasing peptide (GRP) receptors in vivo that are overexpressed in prostate, breast, and small-cell lung carcinoma. We have synthesized a library of GRP receptor-avid nanoplatforms by conjugating gold nanoparticles (AuNPs) with BBN peptides. Cellular interactions and binding affinities (IC(50)) of AuNP-BBN conjugates toward GRP receptors on human prostate cancer cells have been investigated in detail. In vivo studies using AuNP-BBN and its radiolabeled surrogate (198)AuNP-BBN, exhibiting high binding affinity (IC(50) in microgram ranges), provide unequivocal evidence that AuNP-BBN constructs are GRP-receptor-specific showing accumulation with high selectivity in GRP-receptor-rich pancreatic acne in normal mice and also in tumors in prostate-tumor-bearing, severe combined immunodeficient mice. The i.p. mode of delivery has been found to be efficient as AuNP-BBN conjugates showed reduced RES organ uptake with concomitant increase in uptake at tumor targets. The selective uptake of this new generation of GRP-receptor-specific AuNP-BBN peptide analogs has demonstrated realistic clinical potential in molecular imaging via x-ray computed tomography techniques as the contrast numbers in prostate tumor sites are severalfold higher as compared to the pretreatment group (Hounsfield unit = 150).
Collapse
|
12
|
Yurt Lambrecht F, Durkan K, Bayrak E. Labeling bombesin-like peptide with 99mTc via hydrazinonicotinamide: description of optimized radiolabeling conditions. J Radioanal Nucl Chem 2010. [DOI: 10.1007/s10967-010-0530-8] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
13
|
Zhao KJ, Shen JK. Advances of gastrin-releasing peptide receptor in treatment of tumors. Shijie Huaren Xiaohua Zazhi 2009; 17:63-67. [DOI: 10.11569/wcjd.v17.i1.63] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
The mammalian gastrin-releasing peptide (GRP), known as autocrine growth factors in tumors, is involved in the pathogenesis and progression of many human malignant tumors, and high expression of its receptor, GRPR, in a large spectrum of human cancers gives support to the conclusion that GRPR is a new molecular target in experimental and clinical cancer therapy. GRPRs may be potential carriers for cytotoxins, immunotoxins or radioactive compounds. Moreover, blocking gastrin-releasing peptide receptor signaling pathways by means of antisence oligonucleotide, RNA interference and its antagonists has exhibited impressive antitumor activity.
Collapse
|